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Abstract
Background: Here we aimed to investigate the effect of COX-2 siRNA on proliferation and angiogenesis of gastric
cancer cells.
Methods: The gastric cancer cell line SGC7901 was transfected with COX-2 siRNA, then the growth and
angiogenesis of cells were detected by in vitro and in vivo assay. Human microarray, RT-PCR and western blot
were used to identify differentially expressed angiogenesis-related molecules in cells with decreased expression of
COX-2.
Results: Down-regulation of COX-2 could significantly inhibit the in vitro and in vivo growth of gastric cancer cells,
and suppress the migration and tube formation of human umbilical vein endothelial cells. Totally 23 angiogenesis-
related molecules were found involved in COX-2-induced angiogenesis suppression. The results of RT-PCR and
western blot showed that down-regulation of COX-2 might inhibit VEGF, Flt-1, Flk-1/KDR, angiopoietin-1, tie-2,
MMP2 and OPN.
Conclusions: COX-2 might mediate tumor angiogenesis and growth, and could be considered as a target for
gastric cancer therapy.
Background
Gastric cancer is the second leading cause of cancer
associated death in the world, particularly in Asian
countries. The treatment outcome of this common
malignancy is still not satisfactory and various che-
motherapeutic attempts in an adjuvant setting have
failed to improve the survival rate in gastric cancer.
Recently, angiogenesis has been found related to hema-
togenous recurrence and poor prognosis in gastric
cancer [1]. Angiogenesis is the growth of new vessels
from existing vasculature. A balance of angiogenic and
angiostatic growth factors tightly controls physiological
angiogenesis. Tipping of this balance towards a
pro-angiogenic environment is termed the ‘angiogenic
switch’ a n do c c u r si ns i t u a t i o n ss u c ha st i s s u eh y p o x i a ,
inflammation or neoplasia [2].
C O X - 2 ,aC O Xi s o e n z y m ec a t alyzing the production
of prostaglandins, has been observed in most gastric
cancer tissues compared with the accompanying normal
mucosa. Studies in different cancers have suggested a
relationship between COX-2 and increased pro-
angiogenic growth factors, in particular VEGF [3].
COX-2 is thought to promote angiogenesis and so drive
the malignant phenotype. Overexpression of COX-2
might contribute to angiogenesis of gastric cancer [4].
However, the potential mechanism underlying the role
of COX-2 in angiogenesis remains unclear.
Here we have demonstrated novel observations that
COX-2 might play important roles in angiogenesis of
gastric cancer through regulation of VEGF, Flt-1, Flk-1/
KDR, angiopoietin-1, tie-2, MMP2 and OPN.
Methods
Cell culture
Human gastric cancer cell line SGC7901 was cultivated
in Dulbecco’s modified Eagle’s medium supplemented
with 10% heat-inactivated fetal calf serum, penicillin
(100 U/ml) and streptomycin (100 μg/ml), in a CO2
incubator (Forma Scientific) [5]. Human umbilical vein
endothelial cells (HUVEC-12; ATCC, Manassas, VA)
w e r eg r o w ni nK a i g h n ’s modification of Ham’sF 1 2
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bicarbonate, 0.1 mg/ml heparin, 0.03 mg/ml endothelial
cell growth supplement and 10% FBS.
Plasmid construction and transfection
The siRNA oligos for COX-2 were designed according
to previous report. Target sequences were aligned to
the human genome database in a BLAST search to
ensure that the choosing sequences were not highly
homologous with other genes. For oligo-1, S:
5’-tttgcatcgatgtcaccatagaacatctatggtgacatcgatgcttttt-3’,
AS: 5’-ctagaaaaagcatcgatgtcacc atagatgttctatggtgacatc-
gatg-3’ For annealing to form DNA duplexes, 100 μM
of each S and AS oligos was used. The duplexes were
diluted and then ligated with mU6pro vector which
previously digested by the Bbs I/Xba I restriction
enzyme and gel purified at room temperature for
30 min. The products were transformed into DH5a
competent cells. Ampicillin-resistant colonies were
chosen, identified by restriction digestion and further
confirmed by DNA sequencing.
SGC7901 cells were planted in six-well plates and cul-
tured in drug-free medium. At 90-95% confluence, cells
were washed twice with PBS, grew in 2 ml of DMEM
without antibiotics. Using Lipofectamine™ 2000 reagent
(Invitrogen, Inc. Carlsbad CA), 2 μgo fm U 6 p r o - C O X -
2siRNA plasmids were transfected into cells according
to the manufacturer’s instructions. The cells transfected
with mU6pro vector alone were served as negative con-
trol. Forty-eight hours later, cells were placed in growth
medium containing G418 (GIBCO) for clone selection.
The expression levels of COX-2 in G418-resistant clones
were evaluated by western blot analysis.
RT-PCR
All of the PCR products were separated on ethidium
bromide stained agarose, and visualized with UV as
described previously [6].
Western blot analysis
The western blot was done as described previously. In
brief, total cellular proteins were prepared and then
quantified by Bradford method [7]. A measure of 80 ug
of lysates were electrophoresed in 12% SDS-PAGE and
blotted on a nitrocellulose membrane (Immoblin-P,
Millipore, Bedford, MA, USA). Membranes were
blocked with 5% fat-free milk powder at room tempera-
ture and incubated overnight with antibody at 4°C. After
three washes for 15 min in PBS-T, the membrane was
incubated with the HRP-conjugated goat anti-mouse
IgG antibody (Wuhan, Hubei, China) for 1 h at room
temperature. The enhanced chemiluminescence (Amer-
sham Life Science, Piscataway, NJ, USA) was added and
monitored for the development of color.
Cell growth assay
Cells were seeded on a 96-well plate at 3 × 10
4 cells/
well. Each sample had four replicates. The medium was
replaced at 2-day intervals. Viable cells were counted by
the 3-[4,5-dimethylthiazol-2-yl]- 2,5-diphenyltetrazolium
bromide (MTT) assay after 2, 4, 6, and 8 days.
Tumor growth in nude mice
Female athymic nu/nu mice, 5-6 weeks of age, were
obtained from FMMU Experimental Animal Co.
(Shaanxi, China) and housed in a pathogen-free facility
for all of the experiments. The logarithmically growing
cells were trypsinized and resuspended in D’Hanks solu-
tion, and 5 × 10
6 cells in 0.2 ml were injected subcuta-
neously into the left flank of mice [8]. Experimental and
control groups had at least 6 mice each. Tumors were
measured twice weekly with microcalipers, and the
tumor volume was calculated according to the formula:
volume = length × (width
2)/2.
Quantification of tumor microvessel density
Tumor microvessel densities (MVD) were quantified by
anti-CD31 immunohistochemistry. Briefly, tumor sec-
t i o n sf r o mn u d em i c ew e r ec u tu s i n gaL E I C Ac r y o s t a t
and the paraffin sections were mounted on positively
c h a r g e dS u p e r f r o s ts l i d e sa n dd r i e do v e r n i g h t .T h e
immunostaining was done according to standardized
protocols.
Tube formation assay
Tube formation assay was performed as described pre-
viously (Chia et al, 2010). Briefly, Confluent HUVEC
cells were harvested and diluted in DMEM with 10%
FBS, which were then seeded on Matrigel-coated 24-
well plates. Cell culture medium was then replaced by
conditioned medium. After 16 h, Matrigel was fixed,
stained with H & E and examined under inverted micro-
scope. The mean tube length in five random fields per
well was quantified by computer software.
Cell migration assay
Briefly, confluent monolayer of HUVEC was cultured
with non-growth factor containing media for 12 h
before harvesting. Harvested cells were suspended in
serum-free DMEM199 and HUVEC cells were seeded
onto tissue culture inserts in triplicate. The inserts were
removed after 8 h culture and washed with PBS. Non-
migrated cells on the upper surface of the inserts were
removed by wiping with cotton swabs. The inserts were
fixed in neutral buffered formalin solution, stained with
hematoxylin and eosin (H & E) and mounted on micro-
scope slides. HUVEC migration was quantitated
by counting the number of cells in three random fields
(!200) per insert.
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The gene expression was compared between SGC7901-
siRNA and SGC7901-vector cells for three times [9].
RNA was extracted from 80-90% confluent cells using
Trizol and purified with RNeasy spin columns (Qiagen,
Valencia, CA) according to the manufacturers’ instruc-
tions. Quality of the RNA was ensured before labeling
b ya n a l y z i n g2 0t o5 0n go fe a c hs a m p l eu s i n gt h e
RNA 6000 NanoAssay and a Bioanalyzer 2100 (Agilent,
Palo Alto, CA). Samples with a peak ratio of 1.8 to 2.0
were considered suitable for labeling. Cy3- or Cy5-
labeled cDNA was generated and the Cy3/Cy5 single-
stranded cDNA/cot1 DNA pellet was resuspended in
hybridization buffer, then the hybridization mix was
applied to GEArray Q Series Human Angiogenesis
Gene Array. The ratios of gene expression were con-
s i d e r e dt ob es i g n i f i c a n ti ft h e yw e r e2o r0 . 5i na t
least two independent experiments. Genes were
assigned to functional families based on information
from LocusLink and PubMed.
Statistical analysis
Data were presented as mean ± standard deviation (S.D.)
unless otherwise specified. Comparisons between groups
were made using the Student-Newman-Keuls test or the
Kruskal-Wallis test. All data were analyzed using the SPSS
software package (SPSS Inc, Chicago, USA). A value of
P < 0.05 was considered significant.
Results
Down-regulation of COX-2 inhibited the growth and
tumorigenecity of gastric cancer cells
As Figure 1s h o w e d ,S G C 7 9 0 1c e l l sw e r et r a n s f e c t e d
and then one resistant clone (SGC7901-siRNA) with sig-
nificantly decreased COX-2 expression and one vector
transfected control clone (SGC7901-vector) were
selected. The results of MTT assay showed that down-
regulation of COX-2 might significantly decrease the
proliferation of SGC7901 cells (Figure 2A). As shown in
Figure 2B, down-regulation of COX-2 might inhibit the
malignant growth of SGC7901 cells in vivo.
Down-regulation of COX-2 inhibited angiogenesis of
gastric cancer cells
As shown in Figure 3, the number of endothelial cells
within the tumors formed by COX-2-downregulating
cells was less than that of tumors formed by control
cells. In order to investigate the angiogenic property of
COX-2 in endothelial cells, the in vitro tube formation
of HUVEC was assessed. As shown in Figure 4, 5,
Figure 1 RT-PCR (left) and western blot analysis (right) of COX-
2 in the vector transfectants SGC7901-V (V) and the siRNA
transfectants SGC7901-siRNA (S). ß-actin was used as loading
control.
Figure 2 Down-regulation of COX-2 suppressed growth of gastric cancer cells in vitro and in vivo. A, The growth rate of the cells was
detected using MTT assay as described in “Materials and Methods”. The value shown was the mean of three determinations. B, tumorigenicity of
the cells in BALB/c nu/nu mice was detected. Each group had at least 6 mice. The volumes of tumors were monitored at the indicated time.
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mation and migration in HUVEC.
Effect of COX-2 on angiogenesis related molecules
Using cDNA microarray, genes were identified differen-
tially expressed between different transfected SGC7901
cells. Compared with control cells, a total of 23 genes
were found to be differentially expressed in COX-2-
downregulating cells, including FGF4, PDGF-BB,
P D G F R B ,P F 4 ,T G F B 2 ,T G F B R 1 ,V E G F ,F L T 1 ,F L K1 ,
a n g i o p o i e t i n - 1 ,a n g i o p o i e t i n - 2 ,T i e 2 ,I F N A 1 ,P R L ,P T N ,
SCYA2, SPARC, TNFSF15, PECAM1, MMP2, SER-
PINF1, THBS2 and OPN. To confirm the microarray
findings, RT-PCR and western blot were undertaken in
gastric cancer cells. Down-regulation of COX-2 might
inhibit VEGF, Flt-1, Flk-1/KDR, angiopoietin-1, tie-2,
MMP2 and OPN (Figure 6).
Discussion
Angiogenesis is an essential process required for the growth
and metastatic ability of solid tumors. Tumor angiogenesis
is the proliferation of a network of blood vessels penetrating
into the cancerous growths to supply nutrients and oxygen
and remove metabolic waste products from tumors. Tumor
angiogenesis is a complex process and involves the tight
interplay of tumor cells, endothelial cells, phagocytes and
their secreted factors, which may act as promoters or inhi-
bitors of angiogenesis [10]. More than a dozen different
proteins (such as VEGF, bFGF, IL8, etc.), as well as several
smaller molecules (such as adenosine, PGE, etc.) have been
identified as angiogenic factors secreted by tumor cells to
mediate angiogenesis [11,12].
Lines of evidence suggest that COX-2 is involved in
the steps of gastric carcinogenesis. Increased expression
Figure 3 Effects of COX-2 on tumor angiogenesis.T h et u m o r
microvessel densities (means) in sections from tumors formed by
the vector transfectants SGC7901-V (V) and the siRNA transfectants
SGC7901-siRNA (S). Tumor samples were immunostained with
antibodies against CD31. Mean ± SD, n = 3. *, P < 0.05 VS. control.
Figure 4 Effects of conditioned media on HUVEC tube
formation. HUVECs were seeded in triplicate on Matrigel-
coated 24-well plates, and incubated for 16 h with control
SGC7901 medium (A) and COX-2-siRNA medium (B).
Figure 5 Effects of conditioned media on HUVEC migration.
Migration assay was performed in a BioCoate Matrigele invasion
chamber. The lower chambers were added with control SGC7901
medium (A) and COX-2-siRNA medium (B).
Figure 6 Expression of VEGF, Flt-1, Flk-1/KDR, angiopoietin-1,
angiopoietin-2, tie-2, MMP2 and OPN in the vector
transfectants SGC7901-V (V) and the siRNA transfectants
SGC7901-siRNA (S) by RT-PCR (left) and Western blot (right).
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which COX-2 expression is correlated with poor prog-
nostic outcome. Up-regulation of cox-2 expression and
activity in the ulcer base not only during the acute
phase of inflammation but also in the ulcer healing
stage and especially in areas of intense tissue repair [13].
It has been found that cyclooxygenase-2 inhibitors have
antiproliferative and antiangiogenic activity in several
types of human cancer. However, the mechanism of
COX-2 in angiogenesis remains unclear.
In this study, the data showed that down-regulation of
COX-2 could significantly inhibit the in vitro and in vivo
growth of gastric cancer cell line SGC7901, and suppress
the migration and tube formation of human umbilical vein
endothelial cells, which was consistent with previous report.
To our knowledge, we have firstly identified a expression
pattern of angiogenesis-related molecules in COX-2-
mediated angiogenesis. The results of RT-PCR and western
blot showed that down-regulation of COX-2 might inhibit
V E G F ,F l t - 1 ,K D R ,a n g i o p o i e t i n - 1 ,t i e - 2 ,M M P 2a n dO P N .
Conclusions
In conclusion, COX-2 might mediate tumor angiogen-
esis and growth, and could be considered as a target for
gastric cancer therapy. It was becoming increasingly
clear that the signals that govern angiogenesis, func-
tioned in complex regulatory networks rather than sim-
ple linear pathways, and that these networks might be
wired differently in different cells or tumor types. The
precise mechanism by which COX-2 brought about
these changes, and which of these changes were primary
or secondary ones, remained to be elucidated.
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